Journal of Clinical Trials
Open Access

Abstract

A Potential Panel of Eight mRNA's Signature for Predicting Biochemical Recurrence Free Survival and Disease Free Survival in Prostate Cancer

Fanyu Peng, Min Wang, Hao Zhang, Xueyun Liu* and Yesong Guo*

Objective: In present study, our objective was to discover an mRNA expression signature capable of predicting the Biochemical Recurrence-free (BCR-free) survival of patients with Prostate Cancer (PCa).

Materials and methods: A cohort of 415 patients with pathologically confirmed Prostate Adenocarcinoma (PRAD) from the TCGA dataset was enrolled and analyzed. Using a specific risk score formula, the patients were categorized into high-risk or low-risk groups. Kaplan-Meier survival analyses and Cox regression analyses were conducted to assess the relationship between the mRNA signature and survival outcomes. Furthermore, the KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis was employed to identify potential biological processes and signaling pathways associated with the mRNA signature. To investigate the effects of gene knockdown, CCK8 assay, and transwell assay were employed to explore changes in cell proliferation and invasion ability.

Results and discussion: Eighty-mRNAs showed significant differential expression with a logFC greater than four and a p-value less than 0.05 when comparing biochemical recurrence. Among these, eight mRNAs demonstrated a significant association with Biochemical Recurrence-free (BCR-free) survival. Utilizing a risk score based on the expression levels of these eight mRNAs, we categorized patients into low-risk and high-risk groups, revealing substantial differences in both BCR-free survival and disease-free survival between the two groups. The Oxytocin signaling pathway was involved in this mRNA signature through KEGG analysis. Additionally, cell experiments provided further evidence that the genes within this mRNA signature can influence the proliferation and invasion functions of PCa cells.

Conclusion: In this study, we have successfully developed a novel signature consisting of eight mRNAs, which is valuable in predicting survival outcomes for PCa patients. The clinical implications and underlying mechanisms of these eight mRNAs require further investigation in future studies. These findings open up promising avenues for future research that could lead to a better understanding of the biological significance and therapeutic potential of these mRNAs in PCa patients.

Published Date: 2023-11-06; Received Date: 2023-10-05